2-nitro-p-toluidine

We are 2-nitro-p-toluidine CAS:89-62-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  2-nitro-p-toluidine
CAS.NO:89-62-3
Synonyms:4-Methyl-2-nitroaniline;3-nitro-4-amino-toluene;MNPT;4-methyl-2-nitrophenylamine;o-nitro-p-methylaniline
Molecular Formula:C7H8N2O2
Molecular Weight:152.15100
 
Physical and Chemical Properties:
Density:1,164 g/cm3
Boiling point:169°C (21 mmHg)
Melting point:115-116 °C(lit.)
Flash point:157°C
Index of Refraction:1.615
 
Specification:
Appearance:Orange  powder
Purity:≥99.0%
 
Packing: 25kg drum
Storage:Storage conditions:-20ºC.Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:An intermediate for organic pigments.
 

2-nitro-p-toluidine


Related News: From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.8-amino-2- (2H-tetrazol-5-il) cromen-4-ona, hidrocloruro CAS:110683-23-3 We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.Clorhidrato de 4-benzhidriloxi-1-metilpiperidina CAS:132-18-3 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?766-11-0 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses.

Related Products
Product Name
N-(2-Hydroxyethyl)piperazine View Details
1-Acetyl-2-imidazolidinone View Details
3-Aminophenol hemisulfate View Details
6,7-bis(2-methoxyethoxy)-1H-quinazolin-4-one manufacturer 3-[2-(4-chlorophenoxy)phenyl]-1-methylpyrrolidine-2,4-dione manufacturer 4-Fluoro-3-Methoxybenzoic Acid manufacturer Methyl 2-methyl-2-phenylpropanoate manufacturer Glycyrrhizic Acid Dipotassium Salt Hydrate manufacturer